# A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

> **NCT04465890** · PHASE2 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 207 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** ASC22
- **DRUG:** sodium chloride

## Key facts

- **NCT ID:** NCT04465890
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2024-08-09
- **Final completion:** 2024-08-09
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2024-12-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04465890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04465890, "A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04465890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*